Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Repurposing tromethamine as inhaled therapy to treat CF airway disease
Mahmoud H. Abou Alaiwa, Janice L. Launspach, Kelsey A. Sheets, Jade A. Rivera, Nicholas D. Gansemer, Peter J. Taft, Peter S. Thorne, Michael J. Welsh, David A. Stoltz, Joseph Zabner
Mahmoud H. Abou Alaiwa, Janice L. Launspach, Kelsey A. Sheets, Jade A. Rivera, Nicholas D. Gansemer, Peter J. Taft, Peter S. Thorne, Michael J. Welsh, David A. Stoltz, Joseph Zabner
View: Text | PDF
Research Article Pulmonology

Repurposing tromethamine as inhaled therapy to treat CF airway disease

  • Text
  • PDF
Abstract

In cystic fibrosis (CF), loss of CF transmembrane conductance regulator (CFTR) anion channel activity causes airway surface liquid (ASL) pH to become acidic, which impairs airway host defenses. One potential therapeutic approach is to correct the acidic pH in CF airways by aerosolizing HCO3– and/or nonbicarbonate pH buffers. Here, we show that raising ASL pH with inhaled HCO3– increased pH. However, the effect was transient, and pH returned to baseline values within 30 minutes. Tromethamine (Tham) is a buffer with a long serum half-life used as an i.v. formulation to treat metabolic acidosis. We found that Tham aerosols increased ASL pH in vivo for at least 2 hours and enhanced bacterial killing. Inhaled hypertonic saline (7% NaCl) is delivered to people with CF in an attempt to promote mucus clearance. Because an increased ionic strength inhibits ASL antimicrobial factors, we added Tham to hypertonic saline and applied it to CF sputum. We found that Tham alone and in combination with hypertonic saline increased pH and enhanced bacterial killing. These findings suggest that aerosolizing the HCO3–-independent buffer Tham, either alone or in combination with hypertonic saline, might be of therapeutic benefit in CF airway disease.

Authors

Mahmoud H. Abou Alaiwa, Janice L. Launspach, Kelsey A. Sheets, Jade A. Rivera, Nicholas D. Gansemer, Peter J. Taft, Peter S. Thorne, Michael J. Welsh, David A. Stoltz, Joseph Zabner

×

Figure 6

Effect of tromethamine (Tham) on nasal pH measurements.

Options: View larger image (or click on image) Download as PowerPoint
Effect of tromethamine (Tham) on nasal pH measurements.
Data represent n...
Data represent nasal pH of healthy volunteers after instillation of 250 μl (A) 0.3 M tromethamine (red dashed line represent the duration of the effect of HCO3–) or (B) 0.3 M xylitol (nonionic control). Data are mean ± SEM; some error bars are hidden by symbols, n = 5, Wilcoxon signed-rank test, *P < 0.05. (C) Nasal pH of subjects with cystic fibrosis (CF) at baseline and after instillation of 250 μl tromethamine. Bar graph on the left represents the mean pH ± SEM. The graph on the right shows pH data from individual subjects over time. Data are mean ± SEM; some error bars are hidden by symbols, n = 6, 1-way ANOVA with Holm-Sidak’s Multiple Comparison Test, **P < 0.01, ***P < 0.005. (D) Transepithelial voltage (Vt) in mV of CF subjects at baseline (B, gray circles) and 30 minutes (closed circles) after exposure to 250 μl 0.3 M tromethamine. n = 6, Wilcoxon signed-rank test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts